Organigram Global Inc. · TSX:OGI

Organigram Global — Q4 2023 Earnings Presentation

48 slides from Organigram Global's earnings presentation, Sep 30, 2023

  1. Slide 1: Investor Presentation

    INVESTOR PRESENTATION NASDAQ (OGI) TSX (OGI) Q4 Fiscal 2023 09 | 30 | 23 1

  2. Slide 2: Cautionary Statement

    CAUTIONARY STATEMENT This document is current as of September 30, 2023, except where otherwise management’s discussion and analysis and other Company documents filed from information under the heading "Cautionary Statement Regarding Certain Non- stated. The information contained in this presentation

  3. Slide 3: Who We Are

    WHO WE ARE 2022 Founded in 2013, we are an award-winning cannabis licensed producer with operations spread across Canada Our Vision: To be a respected global leader in the emerging cannabis movement 2023 Our Mission: To delight consumers with trusted brands that deliver innovative cannabis products

  4. Slide 4: Our Strategy

    OUR STRATEGY INNOVATION CONSUMER FOCUS EFFICIENCY EXPANSION Leverage our brands, product portfolio and culture of innovation to: Increase Drive Deliver long-term Reach market share profitability shareholder value new markets 4

  5. Slide 5: Near-Term Strategy

    NEAR-TERM STRATEGY • Organigram continues to demonstrate a track record of innovation informed by consumer research, resulting in market share increases in several categories: • Revolutionized hash with SHRED X Rip-Strips • First to market with ingestible extracts and milled flower • Introducing who

  6. Slide 6: Long-Term Strategy

    LONG-TERM STRATEGY • Organigram has strategically deployed capital to fuel automation, production efficiency, and product consistency needed to attract and retain international distribution partners: • Production and packaging lines for gummies, milled flower, and pre-rolls are now highly automated

  7. Slide 7: Organigram Key Strengths

    ORGANIGRAM KEY STRENGTHS STRONG STATE-OF-THE- HIGH NATIONAL & INNOVATION EXCELLENCE IN BALANCE SHEET ART FACILITIES PERFORMING INTERNATIONAL FOCUS EXECUTION REACH • Negligible debt (less • Moncton facility is one • $233.6M gross • National sales and • First to market with • Consumer insights- than $

  8. Slide 8: BAT Strategic Investments in Organigram

    BAT STRATEGIC INVESTMENTS IN ORGANIGRAM March 2021 - $221M strategic investment from subsidiary of BAT for 19.9% equity interest1 in Organigram • Product Development Collaboration (PDC) with formation of a Center of Excellence (CoE) at our Moncton campus • Focused on developing the next generation o

  9. Slide 9: Established Trend of Revenue Growth

    ESTABLISHED TREND OF REVENUE GROWTH $233.6 Annual Revenue $ millions $209.1 $161.6 $145.8 $109.8 $103.3 $97.5 $86.7 $80.4 $79.1 1 F2019 F2020 F2021 F2022 F2023 Net Revenue Gross Revenue 1. Fiscal 2023 represents 13 months due to a change in 9 Organigram's year end.

  10. Slide 10: Significant International Sales Growth

    SIGNIFICANT INTERNATIONAL SALES GROWTH $18.9 $15.1 INTERNATIONAL NET REVENUE1 $ millions High margin international sales expected to increase further in F2024 $3.8 1. International shipments do not attract Canadian Federal excise taxes and therefore gross, and net revenues are equal. 2. Fiscal 2023

  11. Slide 11: Quarterly Updates & Highlights

    QUARTERLY UPDATES & HIGHLIGHTS Q4 F2023 11

  12. Slide 12: A Leading Canadian LP

    A LEADING CANADIAN LP #2 market share among Canadian LPs1 #1 share for milled flower, #1 in hash, #1 in gummies, #2 in edibles, #3 in pre-rolls, #3 in flower1 #1 LP in Atlantic Canada, #3 in Ontario, #3 in Quebec1 1. As of September 30, 2023 – Multiple Sources (Hifyre, Weedcrawler, provincial boards

  13. Slide 13: Adjusted Gross Margin

    ADJUSTED GROSS MARGIN $40.2 $33.4 ADJUSTED GROSS MARGIN1 $ millions and % of Net Revenue 1. Adjusted gross margin is a non-IFRS financial measure 26% 24% 23% not defined under IFRS and which does not have any $3.6 standardized meaning under IFRS; please refer to the cautionary statement at the begin

  14. Slide 14: Adjusted EBITDA

    ADJUSTED EBITDA $6.0 $3.5 ADJUSTED EBITDA1 $ millions 1. Adjusted EBITDA is a non-IFRS Financial Measure not defined by and does not have any standardized meaning under IFRS; please refer to the cautionary statement at the beginning of this document and the Company’s 2023 MD&A for definitions and a

  15. Slide 15: F2023 Market Successes

    F2023 MARKET SUCCESSES • Organigram achieved the #2 national market share position1 • Held the #1 position in milled flower, the #1 position in concentrates, and moved into the #1 position in gummies nationally1 • Introduced Tube-Style Pre-Rolls and went from #10 to #3 market share in overall Pre-Ro

  16. Slide 16: F2023 Strategic Highlights

    F2023 STRATEGIC HIGHLIGHTS • First U.S. strategic investment and technical arrangement with Phylos to commercialize THCV and convert a portion of garden to cost effective seed-based production • Accelerated focus on vapes with a strategic investment in Greentank, a leading vaporization technology co

  17. Slide 17: Strong Balance Sheet and Liquidity

    STRONG BALANCE SHEET AND LIQUIDITY • On September 30, 2023, the Company had cash of $51.8 million (including restricted cash) • $124.6 million follow-on investment from BAT announced November 6, 2023, expected to enhance capital position and fuel international growth • Negligible debt (less than $0.

  18. Slide 18: Q4 Fiscal 2023 Key Financial Metrics

    Q4 FISCAL 13- 12- months en months end Q4‘23 Q4‘22 % Change ded Sep‘23 ed Aug‘22 % Change 2023 KEY Gross revenue 71.5 65.7 9% 233.6 209.1 12% Excise taxes (25.4) (20.2) 26% (72.0) (63.3) 14% FINANCIAL Net revenue1 46.0 45.5 1% 161.6 145.8 11% Cost of sales 42.9 36.7 17% 136.4 119.0 15% METRICS Gross

  19. Slide 19: Fiscal 2024 Outlook

    FISCAL 2024 OUTLOOK • Expecting solid Fiscal ‘24 net revenue – anticipated to be higher than Fiscal ‘23 due to: • Strong market share – positioned as the #2 LP1 • Continued expansion of product portfolio in multiple segments • Focus on expansion in key growth categories of vapes and pre-rolls • Grea

  20. Slide 20: Potential Upside for Gross Margins

    POTENTIAL UPSIDE FOR GROSS MARGINS • Improved economies of scale and efficiencies as cultivation and production volumes continue to increase • Leverage the increased annual capacity at Moncton facility and dialing in 2023 capex investments – targeting ~$10 million in savings in F2024 • Conversion of

  21. Slide 21: Brand Portfolio

    BRAND PORTFOLIO 21

  22. Slide 22: Well-Rounded Brand Portfolio

    WELL-ROUNDED BRAND PORTFOLIO NEW Pricing Segment Value Value Value Mainstream Mainstream Mainstream Premium Craft Pre-Milled Flower, Pre-Roll Joints, Pre-Rolls, Available / Whole Flower, Hashish, Infused Gummies, Whole Flower CBD & Minor Infused Pre-Rolls, Whole Flower Planned Whole Flower Pre-Roll

  23. Slide 23: Consumer Segmentation

    CONSUMER SEGMENTATION Cheap High Male Lifestyle Passionate Female Therapeutic Problem SEGMENT Premium Craft Seeker Social Dabbler Urban Trend Follower Chaser Enthusiast Believer Solver % CONSUMERS 15% 13% 6% 12% 20% 25% 10% Canada vs ATL % VOLUME Canada vs ATL 23% 12% 11% 27% 13% 3% 11% • Seeking th

  24. Slide 24: Dynamic Brand Performance

    DYNAMIC BRAND PERFORMANCE Rip-Strip Sales Have Exploded Monjour Market Share has Doubled Organigram is the #1 LP in vs. Prior Year Concentrates • Launched in March 2023 • Monjour holds over half of the pure- • Organigram holds >23% of national • Over 260K units sold approaching CBD national market s

  25. Slide 25: Dynamic Brand Performance

    DYNAMIC BRAND PERFORMANCE SHRED X Heavies – 40%+ THC Infused Pre-Rolls (IPRs) Tube Style Pre-Rolls • IPR's are fastest growing category in Canada (125% • Tube style pre roll segment growing at 30% year- YOY growth) over-year • Launched end of May 2023 • Organigram market share in tube-style pre-roll

  26. Slide 26: Operations

    OPERATIONS 26

  27. Slide 27: Moncton: State-of-Art Cultivation Centre

    MONCTON: STATE-OF- ART CULTIVATION CENTRE ~85,000 kg/year of low-cost high-quality indoor flower • 500,000 sq. Ft. campus located in Moncton, NB – One of the largest indoor cannabis facilities in the world • Unique, modular, three-tier, strain-specific grow rooms with 245,000 sq. Ft. of growing spac

  28. Slide 28: Lac Supérieur: Premium Quality Cannabis and Hash Production

    LAC SUPÉRIEUR: PREMIUM QUALITY CANNABIS AND HASH PRODUCTION Acquired in Q2 F2021 - drove #1 market share of hash by Q1 F20231 • Located in Lac-Supérieur, Québec (near Mont-Tremblant) • Producer of hang dried, trimmed by hand, artisanal craft cannabis, and premium Afghan-style hash • 30,000 sq. ft. e

  29. Slide 29: Winnipeg: Edibles and Derivatives Facility

    WINNIPEG: Large scale automation and innovative products EDIBLES AND • Purpose-built, highly automated, 51,000 sq. ft. facility with state-of-the-art equipment • Designed to produce nutraceutical-grade cannabis edibles, including pectin, gelatin, DERIVATIVES and sugar-free soft chews (gummies), toff

  30. Slide 30: Strategic Investments

    STRATEGIC INVESTMENTS 30

  31. Slide 31: Investment in Disruptive Vaping Technology

    INVESTMENT IN DISRUPTIVE VAPING TECHNOLOGY • In March of 2023, Organigram invested C$5.5M into Greentank, a vape R&D firm and hardware manufacturer • Greentank's heating technology is the first meaningful innovation in the vape space in almost a decade • Invented a novel heating element which replac

  32. Slide 32: Investment in Seed Genetics & THCV

    INVESTMENT IN SEED GENETICS & THCV • In May of 2023, Organigram made its first investment into the U.S cannabis market by issuing a strategic convertible loan to Phylos • Phylos will enable Organigram to accelerate the launch of products containing THCV in the Canadian market – THCV provides consume

  33. Slide 33: Investment in Disruptive Technology-Biosynthesis

    INVESTMENT IN DISRUPTIVE TECHNOLOGY-BIOSYNTHESIS BIOSYNTHESIS How it works? A proprietary Biosynthesis can be used to produce cannabinoids that are identical to those • 49% ownership (if convertible debt converted) of Hyasynth cannabinoid manufacturing produced by the plant itself. Biologicals Inc.,

  34. Slide 34: International

    INTERNATIONAL 34

  35. Slide 35: Key International Supply Arrangements

    KEY INTERNATIONAL SUPPLY ARRANGEMENTS • Currently shipping to medical markets in Australia and Israel • In F2023 shipped $18.9 million in flower vs. $15.1 million in full year F2022 • November 17, 2022: entered into a new multi-year Strategic Agreement with Canndoc to supply up to 20,000kg of dry fl

  36. Slide 36: Appendix

    APPENDIX 36

  37. Slide 37: March 2021 BAT Transaction Summary

    MARCH 2021 BAT TRANSACTION SUMMARY • Subsidiary of BAT subscribed for 58.3M common shares of Organigram, which represented a 19.9% equity interest in March 20211 on a post-transaction basis • Total proceeds to Organigram in March 2021 of ~C$221 million (the “Investment Proceeds”) Investment • The pr

  38. Slide 38: November 2023 BAT Transaction Summary

    NOVEMBER 2023 BAT TRANSACTION SUMMARY • Subject to requisite Organigram shareholder approval, regulatory approvals and other conditions, subsidiary of BAT to subscribe for, in aggregate, ~38.7 million shares of Organigram, over three tranches, at C$3.2203/share. • Total gross proceeds to Organigram

  39. Slide 39: An uplifting & vibrant value brand focused on convenience

    An uplifting & vibrant value brand focused on convenience. Tropic Thunder 7g pre-milled Wild Berry Blaze SHRED’ems Gnarberry 1g 510 vape SHRED X Rip Strips 39

  40. Slide 40: An imaginative brand with iconic strains and stellar extracts

    An imaginative brand with iconic strains and stellar extracts. Holy Mountain Mac-1 3.5 g, R*ntz 3.5g, Pressed Hash 40

  41. Slide 41: Delivering high-quality ounces in a variety of strains

    Delivering high-quality ounces in a variety of strains. Pink Cookies I.C.C. Ultra Sour 41

  42. Slide 42: CBD and minor cannabinoid gummies

    CBD and minor cannabinoid gummies, designed for a personal wellness ritual. Monjour Berry Good Day Monjour Orchard Medley 42

  43. Slide 43: A premium brand focused on flower & innovation

    A premium brand focused on flower & innovation. Limelight 3.5g dried flower Edison JOLTS – Electric Lemon Cherry Limelight Bubble Hash Joints 43

  44. Slide 44: Premium hash, inspired by the timeless tradition of hashish

    Premium hash, inspired by the timeless tradition of hashish. Tremblant 2g Hash 44

  45. Slide 45: Craft cannabis featuring rare cultivars

    Craft cannabis featuring rare cultivars grown with utmost attention and care. Laurentian Saisons 3.5 g 45

  46. Slide 46: Q4 Fiscal 2023 Select Balance Sheet Metrics

    Q4 FISCAL 2023 SELECT BALANCE SHEET METRICS SELECT BALANCE SHEET METRICS September 30, 2023 Aug 31, 2022 % Change Cash & short-term investments (excluding restricted cash) 33,864 98,607 (66)% Biological assets & inventories 80,953 68,282 19% Other current assets 50,066 54,734 (9)% In $000s unless Ac

  47. Slide 47: Q4 Fiscal 2023 Capital Structure

    Q4 FISCAL 2023 CAPITAL STRUCTURE Sept 30, AUGUST 31, in $000s 2023 2022 Current and long-term debt 155 235 Shareholders’ equity 272,093 508,058 Total debt and shareholders’ equity 272,048 508,293 in 000s Outstanding common shares 81,162 313,816 Options 2,830 11,051 Warrants 4,236 16,944 Top-up right

  48. Slide 48: A Canadian Cannabis Leader

    A CANADIAN CANNABIS LEADER NASDAQ (OGI) TSX (OGI) 48

Organigram Global — Q4 2023 Earnings Presentation on 6ix